tesirine

MP-PEG8-VA-PABC-PBD Dimer is a drug-linker conjugates for ADC which is used in the treatment of several cancers. PBD Dimer is a DNA alkylating which inhibits DNA replication[1].

Loncastuximab tesirine, a human cluster of differentiation 19 (CD19)-directed antibody-drug conjugate (ADC), binds to CD19 on the cell membrane, facilitating rapid internalization and inducing cell apoptosis. This mechanism makes it a valuable asset in researching diffuse large B-cell lymphoma [1] [2].

Epratuzumab Tesirine (ADCT-602) is a novel CD22-targeted antibody-drug conjugate (ADC). This compound comprises a pyrrolobenzodiazepine (PBD) dimer and the active payload SG3249.

Rovalpituzumab tesirine (SC-002) is an antibody-drug conjugate (ADC) with anticancer properties. It consists of the DLL3-targeting antibody, Rovalpituzumab, which is linked to a cytotoxic pyrrolobenzodiazepine compound via a protease-cleavable linker. Rovalpituzumab tesirine is utilized in research concerning small cell lung cancer (SCLC).

Camidanlumab tesirine (ADCT 301) is an ADC consisting of a human IgG1 antibody, HuMax-TAC, targeting CD25, which is conjugated through a dipeptide-cleavable linker to pyrrolobenzodiazepine (PBD) dimer payloads. The drug-antibody ratio (DAR) of Camidanlumab tesirine is 2.3. It binds to human CD25 with picomolar affinity and exhibits potent and selective cytotoxicity against human lymphoma cell lines expressing CD25.

PBD dimer-4 (Compound 7) is a C1-substituted PBD dimer. This compound exhibits high DNA-binding affinity, effective DNA cross-linking ability, and potent cytotoxicity against MDA-MB-231 cells (IC50: 236 nM). PBD dimer-4 serves as a payload in the ADC drug Loncastuximab tesirine, utilized for treating various cancer types.

Camidanlumab (HuMax-TAC) is a humanised monoclonal antibody against CD25/IL-2Rα, commonly utilised in the synthesis of the ADC molecule Camidanlumab tesirine.

Loncastuximab (RB4v1.2) is a monoclonal antibody inhibitor targeting CD19 with antitumor activity. It is used in research on non-Hodgkin lymphoma (NHL) and diffuse large B-cell lymphoma (DLBCL), and for synthesizing ADC molecules such as Loncastuximab tesirine.

SG3199-Val-Ala-PAB is an intermediate in the synthesis of Tesirine, a conjugate of agent-linker for antibody-drug conjugates (ADCs) used in cancer research [1].

Mal-PEG8-Val-Ala-PABC is a cleavable linker used in the synthesis of Tesirine, an agent-linker conjugate for Antibody-Drug Conjugates (ADC) [1].

Val-Ala-PABC-Exatecan is a drug-linker conjugate comprising the cleavable linker Tesirine and the topoisomerase I inhibitor Exatecan, used in synthesising antibody-drug conjugates (ADCs).

Val-Ala-PABC-Exatecan trifluoroacetate is a drug-linker conjugate for antibody-drug conjugates (ADC), comprising a cleavable Tesirine linker, Val-Ala-PABC, and the topoisomerase I inhibitor Exatecan. This compound facilitates the synthesis of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

Val-Ala-PAB is a building block in the synthesis of Tesirine (a.k.a. SG3249), a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload. Reagent in the preparation of pyrrolobenzodiazepine dimers and their antibody conjugates containing pepti

Olintatug (ADCT-901) is a highly specialized antibody-drug conjugate (ADC) targeting Kidney-Associated Antigen 1 (KAAG1). It comprises a humanized monoclonal antibody conjugated to a potent pyrrolobenzodiazepine (PBD) dimer cytotoxin via a cathepsin-cleavable linker. Olintatug specifically binds to KAAG1 on tumor cell surfaces, internalizes, and releases the PBD dimer, which induces lethal DNA interstrand cross-links, blocking cell division. It is investigated for KAAG1-expressing solid tumors, including ovarian and triple-negative breast cancers.

Alloc-Val-Ala-OH (((Allyloxy)carbonyl)-L-valyl-L-alanine) serves as a building block in the synthesis of Tesirine, which is a clinical antibody-drug conjugate (ADC) featuring a pyrrolobenzodiazepine (PBD) dimer payload. The Val-Ala sequence is cleaved specifically by cathepsin B. The Alloc group is stable towards piperidine and TFA, yet can be easily removed under mild conditions via palladium-catalyzed allyl transfer.